Gunnar Tepe MD, Presenter: Research Consultant, Johnson & Johnson Research Consultant, Cook Group Incorporated Research Consultant, sanofi-aventis Group Research Consultant, Abbott Laboratories Research Consultant, Bayer AG

Thomas Zeller, Abstract Co-Author: Consultant, sanofi-aventis Group Speaker, sanofi-aventis Group Consultant, C.R. Bard Speaker, C.R. Bard Consultant, Johnson & Johnson Speaker, Johnson & Johnson Consultant, ev3 Inc Speaker, ev3 Inc Consultant, Boston Scientific Corporation Speaker, Boston Scientific Corporation Consultant, Straub Medical AG Speaker, Straub Medical AG Consultant, Invatec srl Speaker, Invatec srl Consultant, BIOTRONIK GmbH & Co KG Speaker, BIOTRONIK GmbH & Co KG Consultant, OptiMed Technologies, Inc Speaker, OptiMed Technologies, Inc Consultant, Edwards Lifesciences Corporation Speaker, Edwards Lifesciences Corporation Research grant, Cook Group Incorporated Research grant, KRAUTH Medical KG GmbH & Co Research grant, Pathway Medical Technologies, Inc Research grant, Abbott Laboratories

Stephan Hoyt Duda MD, Abstract Co-Author: Nothing to Disclose

Claus Detlef Claussen MD, Abstract Co-Author: Nothing to Disclose

Stephan Heller, Abstract Co-Author: Nothing to Disclose

Iris Baumgartner, Abstract Co-Author: Nothing to Disclose

 

   

 

 

Endovascular treatment of TASC D lesionsion in the superficial femroal artery has a high technical success rate. Long-term patency might be increased by anti-platelet therapy.

Tepe, G, Zeller, T, Duda, S, Claussen, C, Heller, S, Baumgartner, I, ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients with Peripheral Arterial Disease (RIO-Trial): Endovascular Treatment of TASC D Lesions.  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/6012198.html